Portal de Periódicos da CAPES

Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience

2021; Elsevier BV; Volume: 21; Issue: 6 Linguagem: Inglês

10.1016/j.clml.2021.02.004

2152-2650

Paula Rodríguez‐Otero, Maialen Sirvent, Ana Pilar González-Rodríguez, Esperanza Lavilla, Alfonso García de Coca, José María Arguiñano, Josep M. Martí, Valentín Cabañas, Cristina Motlló, Erik de Cabo, Cristina Encinas, Ilda Murillo, José‐Ángel Hernández‐Rivas, Ernesto Pérez Persona, Felipe Casado, Antònia Sampol, Ricarda García, María Jesús Blanchard, M Fernandez Anguita, Ana Lafuente, Belén Íñigo, Aurelio López, Paz Ribas, Mario Arnao, Roberto Maldonado, Joan Bladé, María‐Victoria Mateos, Juan José Lahuerta, Jesús F. San Miguel,

Cancer Treatment and Pharmacology

Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide. Indeed, with currently approved treatments, median progression-free survival (PFS) in the lenalidomide-refractory setting is less than 10 months, reflecting the difficulty in treating this patient population. Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations.A real-world study was conducted by the Spanish Myeloma group in a cohort of patients with RRMM treated with pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex). One hundred patients were treated with a median of 3 prior lines of therapy.Overall response rate was 39%, with a clinical benefit rate of 93%. Median PFS was 7.6 months; median overall survival (OS) was 12.6 months. Median PFS and OS survival were consistent across the different subgroups analyzed. Prolonged PFS and OS were found in patients with responsive disease.Our results compared favorably with those obtained with different pomalidomide-based combinations in a similar patient population. PomCiDex remains a manageable, cost-effective, and all-oral triplet combination for RRMM patients.